SU1329615A3 - Способ получени производных алканов или алкенов - Google Patents
Способ получени производных алканов или алкенов Download PDFInfo
- Publication number
- SU1329615A3 SU1329615A3 SU823503159A SU3503159A SU1329615A3 SU 1329615 A3 SU1329615 A3 SU 1329615A3 SU 823503159 A SU823503159 A SU 823503159A SU 3503159 A SU3503159 A SU 3503159A SU 1329615 A3 SU1329615 A3 SU 1329615A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- sub
- compounds
- cyclopentyl
- hydrogen
- carbon atoms
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 18
- 150000001336 alkenes Chemical class 0.000 title claims description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 21
- -1 2,3-epoxypropoxy, 2,3-dihydroxypropoxy Chemical group 0.000 claims abstract description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 8
- 239000001257 hydrogen Substances 0.000 claims abstract description 7
- 239000002253 acid Substances 0.000 claims abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims description 3
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 10
- 230000001076 estrogenic effect Effects 0.000 abstract description 7
- 230000001833 anti-estrogenic effect Effects 0.000 abstract description 6
- 230000000259 anti-tumor effect Effects 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract description 4
- 239000000328 estrogen antagonist Substances 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 4
- 150000003839 salts Chemical class 0.000 abstract description 4
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 231100000252 nontoxic Toxicity 0.000 abstract 2
- 230000003000 nontoxic effect Effects 0.000 abstract 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000005336 allyloxy group Chemical group 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229960005309 estradiol Drugs 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 201000008274 breast adenocarcinoma Diseases 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 229930182833 estradiol Natural products 0.000 description 5
- 210000004291 uterus Anatomy 0.000 description 5
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 4
- 229960003387 progesterone Drugs 0.000 description 4
- DQYUFNIMGXHBGT-UHFFFAOYSA-N 4-(2-cyclopentyl-1-phenylbutyl)phenol Chemical compound C1CCCC1C(CC)C(C=1C=CC(O)=CC=1)C1=CC=CC=C1 DQYUFNIMGXHBGT-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 102000015694 estrogen receptors Human genes 0.000 description 3
- 108010038795 estrogen receptors Proteins 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PUKBHBOUKVQSSV-UHFFFAOYSA-N 1-(2-cyclopentyl-1-phenylbut-1-enyl)-4-methoxybenzene Chemical compound C=1C=CC=CC=1C(C=1C=CC(OC)=CC=1)=C(CC)C1CCCC1 PUKBHBOUKVQSSV-UHFFFAOYSA-N 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010067572 Oestrogenic effect Diseases 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000003418 antiprogestin Substances 0.000 description 2
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003245 coal Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 229960004616 medroxyprogesterone Drugs 0.000 description 2
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 2
- 230000003623 progesteronic effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- YADFIMYGTLAONQ-UHFFFAOYSA-N 4-(1-phenylbut-1-enyl)phenol Chemical compound C=1C=C(O)C=CC=1C(=CCC)C1=CC=CC=C1 YADFIMYGTLAONQ-UHFFFAOYSA-N 0.000 description 1
- CMTSCGCIUZBCEL-UHFFFAOYSA-N 4-(2-cyclopentyl-1-hydroxy-1-phenylbutyl)phenol Chemical compound C=1C=CC=CC=1C(O)(C=1C=CC(O)=CC=1)C(CC)C1CCCC1 CMTSCGCIUZBCEL-UHFFFAOYSA-N 0.000 description 1
- AJTURHVTEJDZPD-UHFFFAOYSA-N 4-(2-cyclopentyl-1-phenylbut-1-enyl)phenol Chemical compound C=1C=CC=CC=1C(C=1C=CC(O)=CC=1)=C(CC)C1CCCC1 AJTURHVTEJDZPD-UHFFFAOYSA-N 0.000 description 1
- RORRRBDVGWLFEF-UHFFFAOYSA-N 4-[4-(hydroxymethyl)hexan-3-yl]phenol Chemical compound CCC(CO)C(CC)C1=CC=C(O)C=C1 RORRRBDVGWLFEF-UHFFFAOYSA-N 0.000 description 1
- ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
- VFZRZRDOXPRTSC-UHFFFAOYSA-N DMBA Natural products COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000003113 alkalizing effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical compound CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- HCFSGRMEEXUOSS-JXEXPEPMSA-N medrogestone Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(C)[C@@]1(C)CC2 HCFSGRMEEXUOSS-JXEXPEPMSA-N 0.000 description 1
- 229960000606 medrogestone Drugs 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
- C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
- C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
- C07C37/001—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by modification in a side chain
- C07C37/002—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by modification in a side chain by transformation of a functional group, e.g. oxo, carboxyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
- C07C37/001—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by modification in a side chain
- C07C37/003—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by modification in a side chain by hydrogenation of an unsaturated part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
- C07C37/11—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms
- C07C37/20—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms using aldehydes or ketones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
- C07C37/50—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions decreasing the number of carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with no unsaturation outside the aromatic ring
- C07C39/11—Alkylated hydroxy benzenes containing also acyclically bound hydroxy groups, e.g. saligenol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
- C07C39/17—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings containing other rings in addition to the six-membered aromatic rings, e.g. cyclohexylphenol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/205—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings
- C07C39/21—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings with at least one hydroxy group on a non-condensed ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/21—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/215—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Epoxy Compounds (AREA)
- Inorganic Insulating Materials (AREA)
- Separation Of Gases By Adsorption (AREA)
- Treating Waste Gases (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB08132240A GB2108486B (en) | 1981-10-26 | 1981-10-26 | Alkane and alkene derivatives and their preparation and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1329615A3 true SU1329615A3 (ru) | 1987-08-07 |
Family
ID=10525401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU823503159A SU1329615A3 (ru) | 1981-10-26 | 1982-10-18 | Способ получени производных алканов или алкенов |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US4556677A (https=) |
| EP (1) | EP0078158B1 (https=) |
| JP (1) | JPS5879934A (https=) |
| AT (1) | ATE22065T1 (https=) |
| AU (1) | AU555477B2 (https=) |
| CA (1) | CA1310974C (https=) |
| DD (1) | DD211548A1 (https=) |
| DE (1) | DE3273219D1 (https=) |
| DK (1) | DK472082A (https=) |
| FI (1) | FI77842C (https=) |
| GB (1) | GB2108486B (https=) |
| HU (1) | HU193268B (https=) |
| IE (1) | IE54586B1 (https=) |
| IL (1) | IL67049A (https=) |
| NO (1) | NO159079C (https=) |
| NZ (1) | NZ202269A (https=) |
| SU (1) | SU1329615A3 (https=) |
| ZA (1) | ZA827742B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2496880C2 (ru) * | 2008-12-12 | 2013-10-27 | СЕЛЕКСИОН, ЭлЭлСи | Биологический синтез дифункциональных алканов из альфа-кетокислот |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2108486B (en) * | 1981-10-26 | 1986-01-29 | Farmos Group Ltd | Alkane and alkene derivatives and their preparation and use |
| US4775660A (en) * | 1984-08-02 | 1988-10-04 | Fernand Labrie | Treatment of breast cancer by combination therapy |
| US4760053A (en) * | 1984-08-02 | 1988-07-26 | Fernand Labrie | Combination therapy for selected sex steroid dependent cancers |
| US4666885A (en) * | 1985-02-08 | 1987-05-19 | Fernand Labrie | Combination therapy for treatment of female breast cancer |
| US4895715A (en) * | 1988-04-14 | 1990-01-23 | Schering Corporation | Method of treating gynecomastia |
| ES2077675T3 (es) * | 1989-03-10 | 1995-12-01 | Endorecherche Inc | Terapia combinada para el tratamiento de enfermedades sensibles a los estrogenos. |
| NL1018247C2 (nl) | 2001-06-08 | 2002-12-10 | Sara Lee De Nv | Inrichting voor het bereiden van een voor consumptie geschikte drank zoals koffie. |
| JP2004010479A (ja) * | 2002-06-03 | 2004-01-15 | Japan Science & Technology Corp | ブロック共重合体とアンスラサイクリン系抗癌剤を含む新規固型製剤及びその製造法 |
| FR3071837B1 (fr) | 2017-09-29 | 2019-11-01 | Institut National De La Recherche Agronomique | Derive de lignine chimiquement stable et procede pour sa preparation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1306604A (fr) * | 1959-03-03 | 1962-10-19 | Ferrosan Ab | Procédé pour préparer des bisphényléthylènes substitués |
| GB1289966A (https=) * | 1968-12-24 | 1972-09-20 | ||
| US3661976A (en) * | 1969-05-16 | 1972-05-09 | Parke Davis & Co | 4,4'-(2-cycloalkyl-alkylidene) diphenols and ethers and esters thereof |
| BE793686A (fr) * | 1972-01-07 | 1973-07-04 | Beecham Group Ltd | Composes di-aryliques biologiquement actifs |
| GB2108486B (en) * | 1981-10-26 | 1986-01-29 | Farmos Group Ltd | Alkane and alkene derivatives and their preparation and use |
-
1981
- 1981-10-26 GB GB08132240A patent/GB2108486B/en not_active Expired
-
1982
- 1982-10-12 FI FI823465A patent/FI77842C/fi not_active IP Right Cessation
- 1982-10-18 SU SU823503159A patent/SU1329615A3/ru active
- 1982-10-21 DE DE8282305612T patent/DE3273219D1/de not_active Expired
- 1982-10-21 EP EP82305612A patent/EP0078158B1/en not_active Expired
- 1982-10-21 AT AT82305612T patent/ATE22065T1/de not_active IP Right Cessation
- 1982-10-22 IE IE2551/82A patent/IE54586B1/en not_active IP Right Cessation
- 1982-10-22 AU AU89702/82A patent/AU555477B2/en not_active Ceased
- 1982-10-22 ZA ZA827742A patent/ZA827742B/xx unknown
- 1982-10-22 NZ NZ202269A patent/NZ202269A/en unknown
- 1982-10-22 IL IL67049A patent/IL67049A/xx not_active IP Right Cessation
- 1982-10-23 JP JP57186650A patent/JPS5879934A/ja active Granted
- 1982-10-25 CA CA000414128A patent/CA1310974C/en not_active Expired - Fee Related
- 1982-10-25 NO NO823537A patent/NO159079C/no unknown
- 1982-10-25 DK DK472082A patent/DK472082A/da not_active Application Discontinuation
- 1982-10-25 DD DD82244246A patent/DD211548A1/de not_active IP Right Cessation
- 1982-10-25 HU HU823395A patent/HU193268B/hu not_active IP Right Cessation
- 1982-10-26 US US06/436,805 patent/US4556677A/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| Kieotha А, et al, J. Am. Chem. Soc. 77, 3024 (1955). Landgrebe J. et al, J, Am, Chem. Soc. 89, 17, 4465 (1967). * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2496880C2 (ru) * | 2008-12-12 | 2013-10-27 | СЕЛЕКСИОН, ЭлЭлСи | Биологический синтез дифункциональных алканов из альфа-кетокислот |
Also Published As
| Publication number | Publication date |
|---|---|
| DE3273219D1 (en) | 1986-10-16 |
| AU555477B2 (en) | 1986-09-25 |
| DD211548A1 (de) | 1984-07-18 |
| FI823465A0 (fi) | 1982-10-12 |
| IE822551L (en) | 1983-04-26 |
| FI823465L (fi) | 1983-04-27 |
| EP0078158A3 (en) | 1984-01-18 |
| NO823537L (no) | 1983-04-27 |
| FI77842B (fi) | 1989-01-31 |
| NO159079C (no) | 1988-11-30 |
| ATE22065T1 (de) | 1986-09-15 |
| ZA827742B (en) | 1983-08-31 |
| HU193268B (en) | 1987-09-28 |
| GB2108486A (en) | 1983-05-18 |
| NO159079B (no) | 1988-08-22 |
| IL67049A (en) | 1987-07-31 |
| GB2108486B (en) | 1986-01-29 |
| US4556677A (en) | 1985-12-03 |
| EP0078158B1 (en) | 1986-09-10 |
| DK472082A (da) | 1983-04-27 |
| NZ202269A (en) | 1985-05-31 |
| CA1310974C (en) | 1992-12-01 |
| AU8970282A (en) | 1983-05-12 |
| JPH0239492B2 (https=) | 1990-09-05 |
| FI77842C (fi) | 1989-05-10 |
| IE54586B1 (en) | 1989-12-06 |
| JPS5879934A (ja) | 1983-05-13 |
| EP0078158A2 (en) | 1983-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU1508955A3 (ru) | Способ получени алкеновых производных или их солей | |
| US6037362A (en) | Tricyclic compounds and drug compositions containing the same | |
| KR101717098B1 (ko) | 디글리시드 에테르 유도체 치료법 및 이의 사용 방법 | |
| SU1329615A3 (ru) | Способ получени производных алканов или алкенов | |
| IE51882B1 (en) | 1,2,2-triphenyl but-1-ene derivatives as well as a method for their production and their use as a pharmaceutical preparation | |
| WO1996003375A1 (de) | 2-phenylindole als antiestrogene arzneimittel | |
| EA017038B1 (ru) | Антагонисты прогестеронового рецептора | |
| FUJITA et al. | Antitumor activity of acylated oridonin | |
| US5147880A (en) | Benzo[a]fluorene compounds | |
| EA004931B1 (ru) | 3, 4, 5-тризамещенные арилнитроны и содержащие их фармацевтические композиции | |
| AU650429B2 (en) | Novel aryloxy alcoyl benzenes, processes for their preparation as well as the pharmaceutical compositions containing them | |
| EP1709155B1 (en) | Compounds and compositions for treating dysproliferative diseases, and methods of use thereof | |
| SU1549485A3 (ru) | Способ получени производных 6-метиленандроста-1,4-диен-3,17-диона | |
| Schneider | 2-Alkyl-substituted 1, 1-bis (4-acetoxyphenyl)-2-phenylethenes. Estrogen receptor affinity, estrogenic and antiestrogenic properties, and mammary tumor inhibiting activity | |
| EP4299569A1 (en) | Fused polycyclic substituted 5-carboxylic acid thienopyrimidine dione compound and use thereof | |
| EP0011372B1 (en) | 1-acyloxyphenyl-1,2-diphenylalkene derivatives, processes for their manufacture and a pharmaceutical composition containing these derivatives | |
| RU2320669C2 (ru) | Целенаправленная химиотерапия опухолей половых органов | |
| RU2060249C1 (ru) | Полициклические биоцидные соединения и фармацевтическая композиция на их основе | |
| Browne et al. | Isomeric Amino Alcohols from the Reaction of Styrene Oxide with Benzylamine | |
| EP0955286B1 (fr) | Dérivés du dihydro ou tétrahydronaphtalène ayant une activité (anti-)oestrogène | |
| US6288249B1 (en) | Vitamin D analogs and methods of preparing these compounds | |
| EP0065692B1 (de) | Erythro-1,2,3-Triphenyl-1-pentanon-Derivate sowie Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel | |
| IE902242A1 (en) | Novel Spirofurane Derivatives | |
| CN113521038B (zh) | 一种麻醉药物组合物及其应用 | |
| Schneider et al. | Catechol estrogens of the 1, 1, 2-triphenyl-1-butene type. Relationship between structure, estradiol receptor affinity, estrogenic and antiestrogenic properties, and mammary tumor inhibiting activities |